SEAGEN INC. Inactive Instrument
Funds and ETFs Seagen Inc.
Equities
SGEN
US81181C1045
Biotechnology & Medical Research
ETFs positioned on Seagen Inc.
| Name | Weight | AuM | 1st Jan change | Investor Rating |
|---|---|---|---|---|
| 14.99% | 215 M€ | +10.68% | - | |
| 2.68% | 1 M€ | 0.00% | - | |
| 2.53% | 0 M€ | 0.00% | - | |
| 2.25% | 0 M€ | 0.00% | - | |
| 1.75% | 4 M€ | +20.15% | ||
| 1.58% | 9 M€ | -4.31% | - | |
| 1.00% | 1,182 M€ | +1.06% | ||
| 0.95% | 8 M€ | +2.44% | ||
| 0.85% | 96 M€ | -1.45% | ||
| 0.61% | 18 M€ | +3.79% | - | |
| 0.30% | 9 M€ | -.--% | - | |
| 0.24% | 22 M€ | 0.00% | - | |
| 0.22% | 3 M€ | 0.00% | - | |
| 0.17% | 52 M€ | +6.98% | ||
| 0.14% | 330 M€ | -.--% | - | |
| 0.12% | 374 M€ | +15.20% | - | |
| 0.10% | 393 M€ | +5.25% | ||
| 0.08% | 35 M€ | +9.63% | - | |
| 0.08% | 9 M€ | +6.26% | - |
Seagen Inc. est spécialisé dans le développement et la commercialisation de thérapies à base d'anticorps monoclonaux destinées au traitement du cancer. Le CA par source de revenus se répartit comme suit :
- ventes de produits (87%) ;
- royalties (8,4%) ;
- revenus issus d'accords de collaboration et de licence (4,6%).
Calendar
2024-07-24
- Q2 2024 Earnings Release (Projected)
| 1st Jan change | Capi. | |
|---|---|---|
| +1.51% | 42.75B | |
| +8.57% | 41.34B | |
| +49.22% | 41.61B | |
| -12.36% | 26.59B | |
| +8.92% | 25.49B | |
| -25.13% | 18.12B | |
| +29.17% | 12.24B | |
| -3.12% | 11.76B | |
| +6.35% | 11B |
